Shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) have earned a consensus recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $31.80.
COLL has been the subject of a number of recent analyst reports. Janney Montgomery Scott set a $26.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Piper Jaffray Companies set a $33.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Jefferies Group raised their price objective on Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Finally, TheStreet raised Collegium Pharmaceutical from a “d+” rating to a “c” rating in a research report on Wednesday, March 7th.
Collegium Pharmaceutical (COLL) traded up $0.14 during trading on Wednesday, hitting $27.00. The stock had a trading volume of 853,332 shares, compared to its average volume of 583,207. The firm has a market cap of $886.22, a PE ratio of -10.80 and a beta of 0.81. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $29.90.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The company’s revenue was up 728.4% compared to the same quarter last year. research analysts predict that Collegium Pharmaceutical will post -0.71 earnings per share for the current fiscal year.
In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total transaction of $132,116.96. Following the completion of the sale, the insider now owns 32,651 shares of the company’s stock, valued at approximately $622,654.57. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total value of $500,200.00. Following the sale, the chairman now directly owns 535,395 shares of the company’s stock, valued at approximately $13,390,228.95. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,928 shares of company stock valued at $1,082,317. 25.76% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of COLL. TIAA CREF Investment Management LLC lifted its position in Collegium Pharmaceutical by 44.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 61,187 shares of the specialty pharmaceutical company’s stock worth $765,000 after acquiring an additional 18,691 shares during the period. Nationwide Fund Advisors raised its stake in shares of Collegium Pharmaceutical by 27.8% during the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Collegium Pharmaceutical by 54.1% during the 2nd quarter. New York State Common Retirement Fund now owns 24,200 shares of the specialty pharmaceutical company’s stock valued at $303,000 after buying an additional 8,499 shares during the last quarter. Northern Trust Corp raised its stake in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Northern Trust Corp now owns 278,425 shares of the specialty pharmaceutical company’s stock valued at $3,483,000 after buying an additional 59,579 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at about $198,000. 87.60% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/17/analysts-set-collegium-pharmaceutical-inc-coll-price-target-at-31-80.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.